Participant Biosketches
Elona Baum, JD (Observer)
General Counsel, California Institute of Regenerative Medicine
Elona Baum is the General Counsel of the California Institute for Regenerative Medicine and a member of CIRM’s executive team. In this capacity, she is responsible for oversight of the legal functions of the agency and for strategic initiatives. She frequently interfaces with the agency’s grantee institutions, the FDA, industry and patient advocacy groups. From 1996 to 2009, Ms. Baum held the positions of Associate General Counsel, and later Director of Regulatory Policy and Strategy at Genentech, Inc. While at Genentech, Ms. Baum also served as the Secretary of Genentech’s Spanish subsidiary, Genentech Espana, and was the lead attorney for strategic acquisitions including manufacturing plants in Spain and in San Diego. She managed a team of attorneys responsible for research collaboration, manufacturing and supply agreements and counseled on matters relating to clinical trial practice, and FDA regulatory compliance matters. Prior to Genentech, Ms. Baum practiced law at private firms where she had an environmental litigation and real estate transactions practice. Ms. Baum received her B.A. in Economics from the University of California, Los Angeles, and her J.D. from the University of San Francisco School of Law. She was selected and served as an extern for Justice John A. Arguelles, California Supreme Court. [Top]
Laura Biron, PhD
Greenwall Fellow, Johns Hopkins Berman Institute of Bioethics
Laura Biron (Cambridge) PhD (Cambridge) is a Research Fellow in Philosophy at Queens’ College, Cambridge, and currently a Greenwall Fellow in Bioethics and Health Policy at Johns Hopkins and Georgetown. Her research and publications to date have focused on: the ontological and justificatory foundations of intellectual property, taxation and global justice. Through Cambridge University’s Forum for Philosophy in Business, she has worked as a consultant for KPMG, Pfizer and, most recently, BT, exploring conceptions of trust and integrity within the communications industry. In 2007, Laura helped to found the non-profit organisation Incentives for Global Health, which is led by Thomas Pogge at Yale University. She has also worked as an advisor to the UK Intellectual Property Office, contributing to their work on the Rationale for Patents. [Top]
Tania Bubela, PhD
Assistant Professor, School of Public Health, University of Alberta, Canada
Tania is an expert in innovation metrics and empirical analysis of commercialization and IP policies. As a professor in the Department of Public Health Sciences at the School of Public Health and adjunct professor in the School of Business at the University of Alberta, she combines legal training with a PhD in biology and expertise in genetics and molecular biology. She provides advice for Government Health and Science agencies, including licensing and research agreement best practices for inter-institutional science projects and databases. She researches large collaborative science networks in genomics and stem cell biology. [Top]
Francesca Cesari, PhD (Observer)
Senior Editor, Nature
Francesca Cesari received her BSc from the University of La Sapienza in Rome, Italy. Following this she earned her PhD from the University of Tübingen in Germany, where she also began her post-doctoral work. She completed her post-doctoral work at The Wellcome Trust/Cancer Research Gurdon Institute in Cambridge, UK. Currently, she is a senior editor at Nature. [Top]
Sarah Chan, BSc(Hons), LLB, MA(Health Care Ethics and Law)
Research Fellow, Institute for Science, Ethics and Innovation, University of Manchester
Sarah Chan is a research fellow at the Institute for Science, Ethics and Innovation, University of Manchester. Her current research interests include the ethics of new biotechnologies and their impact on humans and our concept of humanity: in particular, genetic manipulation, enhancement and interspecies technology. Prior to this, she conducted work on the EU-CLEMIT project involving the ethics of “creating and redesigning human beings”, including ethics in gene and cell therapy, artificial and assisted reproductive technologies, genetic modification and enhancement; the ethics of stem cell research; and regulation of new technologies and public policy. She has previously worked on regulation of embryo and stem cell research in Australia and public attitudes and education regarding gene technology. She conducted laboratory-based research in molecular biology, examining the genetics of male reproduction; and trained as a lawyer specialising in legal theory, health care law and scientific regulation. [Top]
Haidan Chen, PhD
Post Doctoral Research Fellow, Center for STS, Zhejiang University
Dr Haidan Chen gained both an MA (2004-2006) and Ph.D (2006-2009) in the Philosophy of Science and Technology at Zhejiang University . She was a visiting postgraduate researcher at the Institute for the Study of Science Technology and Innovation (ISSTI), the University of Edinburgh, UK (2006-2007). She was an exchange student of the European Union 6th Research Framework project BIONET (Ethical Governance of Biological and Biomedical Research: Chinese-European Co-operation), and visited the Science and Technology Studies Unit (SATSU), the University of York, UK, and the Life Science Governance Research Platform, the University of Vienna, Austria, in May 2008. Her current research relates to the governance of biomedical research, in particular stem cell translational research, biobanks, and biomarkers. More generally, her research interests embrace bioethics, the biopolitics of science and technology, and biomedical innovation. She is working with the European Union 7th Research Framework project REMEDiE (‘Regenerative Medicine in Europe: Emerging Needs and Challenges in a Global Context’) and the UK ESRC (The Economic and Social Research Council) funded project ‘State Strategies of Governance in Global Biomedical Innovation: the Impact of China and India. [Top]
Jorge Contreras, JD
Director, Intellectual Property Program, Washington University in St. Louis School of Law
Jorge L. Contreras is Senior Lecturer in Law and Acting Director of the Intellectual Property Program at Washington University School of Law. His current research focuses on the intersection of law and science. In particular, he studies the patenting of human genetic material, policies surrounding the public release of genomic data, the creation of “science commons” and ethical issues connected with research use of human tissue. Professor Contreras teaches various courses covering intellectual property as well as the Law and Regulation of Science (which addresses public health issues such as quarantine, environmental contamination, vaccination, public health interventions and medical research ethics). He has recently published several articles on commons formation and data release in the genomic sciences and continues to study this rapidly-developing area closely. Prior to joining the faculty Professor Contreras spent 17 years as a practicing attorney in Boston, London and Washington, DC. In his law practice he helped to establish a number of public-private consortia engaged in biomedical and genomics research, including the SNP Consortium. He has served on the National Advisory Council for Human Genome Research of NIH, and is Chair of the Committee on Technical Standardization of the ABA Section of Science & Technology Law. He edited the ABA’s 2007 Standards Development Patent Policy Manual, and has published numerous articles relating to standards and technology law. Professor Contreras is also a Scholar at the Washington University Institute for Public Health. He is an honors graduate of Harvard Law School, with undergraduate degrees in English and electrical engineering from Rice University. He clerked for Chief Justice Thomas R. Philips of the Texas Supreme Court. [Top]
Robert Cook-Deegan, MD
Director, IGSP Center for Genome Ethics, Law & Policy
Robert Cook-Deegan became Director of the IGSP’s Center for Genome Ethics, Law & Policy in July 2002. He was previously director of the Robert Wood Johnson Foundation Health Policy Fellowship program (2000- 2002) at the Institute of Medicine (IOM), National Academy of Sciences, a Robert Wood Johnson Health Policy Investigator at Georgetown University (1999-2002), and a seminar leader at Stanford-in-Washington (1996- 2003). He worked at The National Academies in various capacities from 1991 until coming to Duke. Dr. Cook- Deegan was a AAAS Congressional Science & Engineering Fellow 1982-3 and spent six years at the congressional Office of Technology Assessment. This followed two years of postdoctoral research on the molecular biology of oncogenes with Lasker Award scientist Raymond L. Erikson, after completing his internship in pathology at the University of Colorado. He received his MD degree from the University of Colorado in 1979 and his bachelor’ s degree in chemistry, magna cum laude, in 1975 from Harvard College. [Top]
Ishan Dasgupta
Research Program Coordinator, Johns Hopkins Berman Institute of Bioethics
Ishan earned his BA (with honors) in Philosophy and Behavioral Biology from Johns Hopkins University. During his undergraduate career he completed an honors thesis on the topic of the neuroscientific investigation of free will under the guidance of Hilary Bok. He was also selected to present at the ASBH’s National Undergraduate Bioethics Conference—making an argument for allowing cognitive enhancement. Before his current position, Ishan was an intern at the Berman Institute for two years. Prior to BI, his work experience included research assistant at the Johns Hopkins Behavioral Psychopharmacology Research Unit, technician at an emergency room, and numerous volunteer positions in clinical settings. [Top]
Matthew DeCamp, MD, PhD
Greenwall Fellow, Johns Hopkins Berman Institute of Bioethics
Matthew DeCamp is currently a Greenwall Fellow in Bioethics and Health Policy and fellow in General Internal Medicine at Johns Hopkins University. His main research examines the impact of intellectual property rules on global distributive justice and access to essential medicines. Other areas of interest include global health, particularly the ethics of short-term medical outreach; theories of normative change, focusing on the normative content of the human right to health; and clinical ethics consultation. Prior to starting at Johns Hopkins in July 2010, he was an internal medicine resident at the University of Michigan (Ann Arbor). He received his MD and PhD in philosophy (“Global Health: A Normative Analysis of Intellectual Property Rights and Global Distributive Justice”) in 2008 from Duke University. [Top]
Peter J Donovan, PhD
Professor of Developmental and Cell Biology and of Biological Chemistry Co-Director, Sue and Bill Gross Stem Cell Center, University of California, Irvine
Peter J Donovan, PhD, is Professor of Developmental and Cell Biology and of Biological Chemistry at the University of California, Irvine and Co-Director of the Sue and Bill Gross Stem Cell Research Center. Dr Donovan’s laboratory studies the molecular mechanisms regulating primordial germ cell development in mice as well as the mechanism regulating the meiotic cell cycle in mammals. His laboratory pioneered the development of pluripotent stem cells from primordial germ cells in mice and, with John Gearhart, developed the same cell type from human germ cells. His research interests center around the mechanisms regulating developmental potency in germ cells and stem cells. His laboratory was one of the first to receive NIH funding to study human embryonic stem (ES) cells and he serves on one of only two NIH study sections that reviews proposed studies on human ES cells. He serves as a member of the board of reviewing editors of Science. [Top]
Ruth Faden, PhD, MPH
Philip Franklin Wagley Professor of Biomedical Ethics, Executive Director, Johns Hopkins Berman Institute of Bioethics, Professor, Department of Health Policy & Management, Johns Hopkins School of Public Health Professor, Department of Medicine, The Johns Hopkins University School of Medicine
Ruth R Faden, PhD, MPH, is the Philip Franklin Wagley Professor of Biomedical Ethics and Executive Director of The Berman Institute of Bioethics at Johns Hopkins University. She is also a Senior Research Scholar at the Kennedy Institute of Ethics, Georgetown University. Dr Faden is the author and editor of numerous books and articles on biomedical ethics and health policy including Social Justice: The Moral Foundations of Public Health and Health Policy (with Madison Powers), A History and Theory of Informed Consent (with Tom L Beauchamp), AIDS, Women and the Next Generation (Ruth Faden, Gail Geller and Madison Powers, eds.), and HIV, AIDS and Childbearing: Public Policy, Private Lives (Ruth Faden and Nancy Kass, eds). Dr Faden is a member of the Institute of Medicine and a Fellow of the Hastings Center and the American Psychological Association. She has served on several national advisory committees and commissions, including the President’s Advisory Committee on Human Radiation Experiments, which she chaired. She is a co-founder of the Hinxton Group, a global community committed to advancing ethical and policy challenges in stem cell science, and the Second Wave project, an effort to ensure that the health interests of pregnant women are fairly represented in biomedical research and drug and device policies. Dr. Faden’s current research focuses on questions of social justice in health policy and global health. She also works on ethical challenges in biomedical science and in women’s health. Dr. Faden’s work in social justice is concentrated on national and global challenges in pandemic influenza planning and response, vaccine policy and funding, health systems design, and access to the benefits of global investments in biomedical research. Dr Faden holds a BA from the University of Pennsylvania, a MA in General Studies in Humanities from the University of Chicago, and a MPH and PhD (Program in Attitudes and Behavior) from the University of California, Berkeley. [Top]
Richard Gold, SJD
Associate Professor, McGill University Faculty of Law President, The Innovation Partnership
Richard Gold teaches in the area of intellectual property and common law property at McGill University’s Faculty of Law. He was the founding director of the Centre for Intellectual Property Policy. His research centres on understanding the links between innovation, intellectual property and development. He led the International Expert Group on Biotechnology, Innovation and Intellectual Property, a transdisciplinary research team that issued a ground-breaking report on the policies and law of innovation and intellectual property. He has published widely in legal and scientific journals on this topic and is the author of Body Parts: Property Rights and the Ownership of Human Biological Materials. Professor Gold leads a cutting-edge initiative to translate academic research in concrete policy for government, industry, universities and NGOs: The Innovation Partnership. TIP is unique in the world: it is a non-profit corporation dedicated to helping public and private actors in developing as well as developed countries better manage their innovation systems. Prior to creating TIP, Professor Gold actively helped the policy community understand the implications of intellectual property policy. [Top]
Gregory Graff, PhD
Assistant Professor, Colorado State University
Gregory Graff’s research interests concern the policy and economics of scientific research, technological innovation, and entrepreneurship. Within the context of agriculture and resources, questions of technology and innovation cut broadly and include changes in industry structure, economic development, global trade, and, reciprocally, influences back on the formation of government science and technology policies. Of particular interest is the role played by intellectual property rights–as incentives for innovation and as marketable assets, but also as a source of transaction costs and inefficiencies in R&D in areas where common access problems may arise. Similarly important is the process of technology transfer, whereby, in the U.S. and many other countries, publicly subsidized research generates private economic activity, seeding the entry of new process technologies, new products, new firms, and, occasionally, even entire new industries. A major theme in my work is the balance or tradeoff between the sometimes complementary and sometimes contradictory public versus private characteristics of knowledge as an economic good or asset. My empirical analysis focuses on the relationship between public and private sector innovation in the life sciences for applications in agriculture, medicine, and energy. [Top]
John Harris, FMedSci, BA, DPhil
Lord Alliance Professor of Bioethics, Director of Institute for Science, Ethics and Innovation, School of Law, University of Manchester Visiting Professor, Department of Philosophy, Logic and Scientific Method, London School of Economics and Political Science
John Harris is the Lord Alliance Professor of Bioethics, Director of the Institute for Science, Ethics and Innovation (iSEI), School of Law, University of Manchester and is joint Editor-in-Chief of The Journal of Medical Ethics, the highest ranked journal globally in Medical Ethics. He was elected a Fellow of the United Kingdom Academy of Medical Sciences (FMedSci) in 2001, is a Fellow of The Hastings Center and has been a member of The United Kingdom Human Genetics Commission since its foundation in 1999, and many other advisory commissions. Recent Books Include: Clones Genes and Immortality, Oxford University Press, 1998, John Harris, Ed; Bioethics, Oxford Readings in Philosophy Series, Oxford University Press, 2001, Justine C Burley and John Harris, Eds; A Companion To Genethics: Philosophy and the genetic revolution, Basil Blackwell, Oxford, 2002 (Blackwell’s Companions to Philosophy series); On Cloning, Routledge. London, 2004; and, Enhancing Evolution: The Ethical Case for Making Better People, Princeton University Press, 2007. [Top]
Søren Holm, PhD
Chair, Centre for Social Ethics and Policy, University of Manchester
Professor of Medical Ethics, University of Oslo
Søren Holm is a Danish doctor and philosopher. He is Professor of Bioethics and Director of the Centre for Social Ethics and Policy at Manchester University and part-time Professor of Medical Ethics at the University of Oslo. He has written extensively on issues in stem cell research. He is a current member of the Nuffield Council on Bioethics and a former member of the Danish Council of Ethics. [Top]
Jim Houlihan, PhD (Observer)
Head of Innovation Policy, UK Intellectual Property Office
Jim Houlihan gained his Ph.D. in immunology at the University of Bristol and currently leads on innovation policy in the Intellectual Property Office. He is a member of the European Research Area Knowledge Transfer group, the European Innovative Medicines Initiative IPR Committee, the NIHR/MRC collaborative clinical agreements committee and is secretariat to the UK’s Lambert IP Group for university-business collaboration. Before this he was a senior patent examiner in the area of life-sciences. [Top]
Ryuichi Ida, LLB, LLM
Ryuichi Ida, LLB, LLM, DEA Professor of International Law, Kyoto University Graduate School of Law, Japan Member, Expert Panel on Bioethics, Council for Science and Technology Policy, Cabinet Office, Japan Member, Bioethics and Biosafety Commission, Ministry of Education, Culture, Sport, Science and Technology, Japan
Professor Ida was born in 1948 and has been a Professor since 1994 at the Kyoto University Graduate School of Law. He was Director of Study (1992) and Professor (2000) at the Hague Academy of International Law (1992). In 1996, he appointed by UNESCO to serve on its International Bioethics Committee (1996-2003; and nominated as Chairperson from 1998 to 2002) where he devoted himself to establishing bioethical standards of universal application. In Japan, Ida has been deeply involved in the formation and implementation of national bioethical norms and guidelines in various fields, in particular, reproductive cloning ban legislation, ethical guidelines for human genome research and Guidelines for Derivationand use of Human ES cells. He is currently working in the Experts Committee on ES Cells Research that reviews at the national level each research protocol concerning ES cell research. He was also Vice-Chairman of the Expert Panel on Bioethics, which is equivalent to a national bioethics committee (2001-2004), where he discussed the status of the human embryo; Chevalier dans l’Ordre des Palmes Académiques (France) (2001). He is the author of numerous publications of international law and bioethics in Japanese, French and English. [Top]
Kazuto Kato, PhD
Associate Professor of Science Communication and Bioethics, Institute for Research in Humanities, Graduate School of Biostudies, Kyoto University Kazuto Kato is Associate Professor of Science Communication and Bioethics at the Institute for Research in Humanities and Graduate School of Biostudies, Kyoto University. He has a PhD degree in developmental biology from Kyoto University. After finishing his postdoctoral research at the Wellcome Trust/Cancer Research UK Gurdon Institute at the University of Cambridge, he started to work in the interface between bioscience and society. He has been working on science communication as well as ethical and social issues of bioscience. He has been a member of Ethics and Public Policy Committee of the ISSCR (International Society for Stem Cell Research) since 2009. He also serves as members of the HUGO (Human Genome Organization) Ethics committee and of the Informed consent and Privacy protection Working Group of the ICGC (International Cancer Genome Consortium). [Top]
Annabelle Lever, PhD
Research Fellow in Interdisciplinary Bioethics, University of Manchester
Annabelle received her doctorate in political science from the Massachusetts Institute of Technology, where she specialised in political and social theory and in political economy. She taught political theory at the University of Rochester, and has held visiting positions at Harvard University and at MIT. More recently she has taught philosophy and public policy at the London School of Economics and at Sciences-Po, in Paris. Her work is mainly focused on problems of privacy, equality and democracy, but she is also interested in ethics and security, intellectual property, bioethics and public health. On Privacy will be published by Routledge and Contemporary Democratic Theory: A Critical Introduction will be published by Oxford University Press. Annabelle was a Senior Fellow in the Program in Ethics and the Professions at Harvard’s Kennedy School of Government in 1999-2000 and a Hoover Fellow in Economic and Social Ethics at Louvain-la-Neuve in Spring 2010.
Jacob Leveridge (Observer)
Wellcome Trust
Jacob has a background in public health research and research ethics. He co-founded Living Knowledge Consulting, a small health impact assessment and health research consultancy, in 2002 and also worked for four years as a Coordinator of two UK National Health Service (NHS) Research Ethics Committees in London, UK. Jacob joined the Wellcome Trust in 2006. His primary responsibility at the Trust is to foster capacity-strengthening in health-related ethics research in the UK and low and middle income countries, by facilitating the submission of high quality applications for funding to the Trust’s Biomedical Ethics Programme. Jacob also contributes to the strategic development of medical humanities at the Trust and sits on the Trust’s International Engagement Funding Committee. [Top]
Robin Lovell-Badge, PhD, FMedSci, FRS
Head, Division of Developmental Genetics, MRC National Institute for Medical Research
Robin Lovell-Badge is Head of the Division of Stem Cell Biology and Developmental Genetics at the MRC National Institute for Medical Research, Mill Hill in London, UK. He is also currently a Distinguished Visiting Professor at the University of Hong Kong and an Honorary Professor in the Department of Anatomy and Developmental Biology at University College, London. Apart from his work on sex determination, for which he received the 1995 Louis Jeantet Prize for Medicine, he has had long-standing interests in how decisions of cell fate are reached during embryogenesis, and in the biology and uses of both embryonic and adult stem cells. He is the author of numerous papers published in peer-reviewed journals detailing his research and has also published on policy and ethical issues surrounding stem cells research. Major themes of his current work include sex determination, development of the nervous system and stem cells in the embryo. For several years he help brief members of parliament and peers on stem cell and embryo research, notably prior to the passing of the Human Fertility and Embryo Act (2008). He continues to serve on several committees for the MRC, the Royal Society, the Academy of Medical Sciences, and also for the HFEA, overseeing and exploring aspects of stem cell and embryo research policy. He has also given talks and participated in meetings discussing the science, politics and ethics of stem cell research in various countries in Europe, the USA, China, Hong Kong, Japan and Brazil. He is also very keen to increase public engagement with science and has participated in many debates in the UK and elsewhere on stem cell research and genetics. [Top]
Debra JH Mathews, PhD, MA
Assistant Director for Science Programs, Johns Hopkins Berman Institute of Bioethics Assistant Professor, Department of Pediatrics, Johns Hopkins University School of Medicine
Debra JH Mathews, Ph.D., M.A., is the Assistant Director for Science Programs for the Berman Institute of Bioethics at Johns Hopkins University. Dr. Mathews earned her B.S. in Biology from the Pennsylvania State University and a Ph.D. in genetics from Case Western Reserve University. Concurrent with her Ph.D., she earned a master’s degree in bioethics from Case. She completed a post-doctoral fellowship in genetics at Johns Hopkins, where she continued her work on human genetic variation and human population history. She also completed the Greenwall Fellowship in Bioethics and Health Policy, which is jointly administered by Johns Hopkins and Georgetown universities. As a Greenwall Fellow, Dr. Mathews worked at the Genetics and Public Policy Center, researching the views of geneticists on their role(s) in science policy formation and public engagement. In addition, during a three-month internship at the Department of Health and Human Services in the Office of the Assistant Secretary for Planning and Evaluation, Office of Science and Data Policy, she worked with the Privacy Advocate on issues related to large data systems. As the Assistant Director for Science Programs, Dr. Mathews is responsible for overseeing the Stem Cell Policy and Ethics program (SCoPE) and the Program in Ethics and Brain Sciences, as well as other bench research-related endeavors in the Berman Institute. Her research interests focus on the intersection of science, public policy and society. [Top]
Reinhard Merkel, Prof, Dr
Universität Hamburg, Institut für Kriminalwissenschaften
Reinhard Merkel holds a professorship in the field of criminal law and the philosophy of law at the University of Hamburg. His research interests include: the dogmatics of criminal law, medical ethics, theories of justice, political philosophy, as well as international law. Prof Merkel worked as editor of the German weekly newspaper Die Zeit from 1988 and 1990. In 1991 he was awarded the “Jean-Amery-Preis für Essayistik”. As a result of his interest and expertise in the field of medical ethics, Prof Merkel also is a member of various medical ethics commissions, such as the “Wiener Ethik Beirat” (Viennese Ethics Commission). His major publications include: Strafrecht und Satire im Werk von Karl Kraus (Criminal law and satire in the work of Karl Kraus) (1994), which received the Award “juristic book of the year 1996, Zum ewigen Frieden – Grundlagen, Aktualität und Aussichten einer Idee von Immanuel Kant (Perpetual Peace – Foundations, Topicality and Prospects of an idea of Imanuel Kant) (1996) edited with R Wittmann, Der Kosovo-Krieg und das Völkerrecht (The Kosovo Conflict and International Law) (Editor) 2000, and a book on ethical and legal issues in research using embryonic stem cells: Forschungsobjekt Embryo. Verfassungsrechtliche und ethische Grundlagen der Forschung an menschlichen embryonalen Stammzellen (2002). Reinhard Merkel has also published numerous articles on criminal law, philosophy, philosophy of law and literature. [Top]
Dianne Nicol, PhD, LLM
Professor, University of Tasmania Australia
Dianne Nicol started her academic career as a scientist, taking her first degree from Manchester University. Her PhD was in the area of cell biology, with particular focus on the development of simple nervous systems. She is now a Professor at the Law and one of the Deputy Directors of the Centre for Law and Genetics (CLG) at the University of Tasmania. The broad theme of the CLG’s research is the regulation of biotechnology, human genetics and stem cell technology. Dianne is particularly interested in the legal issues associated with the commercialisation of genetic knowledge and patenting of genetic inventions. Currently her two major research projects focus on access and benefit sharing issues in biobanking and patent pooling. The patent pooling project involves an assessment of how the current Australian biotechnology industry is working and an examination whether patent pooling is a feasible/desirable option. Previously Dianne was involved in a related collaborative project with Janet Hope and John Braithwaite from the Australian National University, which focused on two other cooperative models of IP management: IP clearinghouses and open source licensing. [Top]
Amanda Odell-West, PhD
Lecturer in Law, School of Law, University of Manchester
Member, Institute for Science, Ethics and Innovation (iSEI) and the Centre for Social Ethics and Policy
Amanda Odell-West joined the School of Law in 2009. She is a member of the Institute for Science, Ethics and Innovation (iSEI) at Manchester University, and a member of the Education Committee of the Chartered Institute of Patent Attorneys (CIPA, London). She is also a member of PIIPA (Public interest intellectual property advisors). Currently, she is course director for Tort (first year LLB), programme director for PG Dip in Intellectual Property Law, and stream director for the Intellectual Property LLM. [Top]
Aurora Plomer BA, MA, LLB, PhD
Chair in Law and Bioethics, Director of SIBLE, School of Law, University of Sheffield Director, Sheffield Institute of Biotechnology Law and Ethics, University of Sheffield
Aurora Plomer has a dual background in Philosophy (BA, MA, PhD) and Law (LLB). She has been a Professor of Law and Bioethics at the University of Sheffield and Director of Sheffield’s Institute of Biotechnology, Law and Ethics (SIBLE) since January 2007. Previously, she was a Reader and Assistant Professor in law at the University of Nottingham (UK) and a lecturer in law at the University of Leeds (UK). She has published widely on the interface between biolaw, bioethics and human rights. Her current research focuses on the emerging ethical and legal issues concerning the impact of IP rights on access to foundational knowledge in the biosciences and on the challenges presented by the search for fundamental norms in morally diverse and pluralistic societies. She was the P.I. of the EU funded project ‘Stem Cell Patents: European Patent Law and Ethics’, a member of the AAA’s working party on Science, Ethics and Human Rights, a member of the UK’s ESRC Policy Impact Group on the Stem Cell Initiative and a scientific adviser to the Stem Cell and Society Programme at the University of Stanford (US). [Top]
Beverly A Purnell, PhD
Senior Editor, Science Magazine
As a Senior Editor at Science Magazine, Beverly Purnell handles manuscripts in the areas of stem cells, developmental biology, gene regulation, reproductive biology, and related fields. Her duties include the recruitment, selection, and scientific editing of papers for publication in Science. Along with colleagues at Science, Dr Purnell has coordinated Special Issues on topics such as Germ Cells, Stem Cells, Reproductive Biology, Developmental Timing, and Women’s Health. Beverly Purnell earned a BS at Shepherd College. Positions held include Research Laboratory Assistant in stone fruit breeding at a USDA Agricultural Research Station and a Summer Fellowship at the National Institute of Allergy and Infectious Disease, National Institutes of Health. She obtained a Master’s Degree and PhD at the Pennsylvania State University with projects in C elegans sex determination and Drosophila gene expression, respectively. Dr Purnell was awarded an Alexander von Humboldt fellowship to do postdoctoral work at the Max Planck Institute in Goettingen, Germany, with research in Drosophila head development and gene regulation. She joined the AAAS and Science staff in 1997. [Top]
Mahendra Rao, MD, PhD
Vice President, Stem Cells at Invitrogen Adjunct Professor, Buck Institute of Age Research Vice President, Medicine at Life Technologies
Mahendra Rao served as Vice President of Research, Stem Cells and Regenerative Medicine of Invitrogen Corp. (Alternatively Life Technologies Corporation) since January, 2006. Dr. Rao is a Scientific Co-Founder of Q Therapeutics, Inc. and serves as its Chief Scientific Consultant and Scientific Advisor. Dr. Rao is an expert in glial stem cell biology and for the last 20 years has acted as a scientific consultant for a broad range of constituencies in academia, government, regulatory affairs and industry. He has been involved in stem cell research for more than a decade. At Invitrogen, he heads its stem cell research and development program. He served as chair of the FDA’s Center for Biologics Evaluation and Research (CBER) Advisory committee as well as Stem Cell Section Chief and Senior Investigator in the laboratory of neuroscience at the National Institute of Aging. Dr. Rao maintains an academic appointment at the Buck Institute on Aging Research and has been a professor at the University of Utah School of Medicine, where his research focused on stem cells of the central nervous system. He has also held associate professor positions at both the Johns Hopkins University and the University of Utah Schools of Medicine (1994-May 2001), and at the National Center for Biological Science in India. Dr. Rao has been on the Board of Thermogenesis Corp. since March 2008. He has been a Member of scientific advisory board at Aastrom Biosciences, Inc. since April 2010. Dr. Rao has served as Chairman of the FDA’s Cell and Gene Therapy Advisory Committee. He has co-authored approximately 250 primary article, reviews, and editorials on different aspects of stem cell biology. He holds M.D. from Bombay University in India and earned his Ph.D. from California Institute of Technology. Dr. Rao also did his Post-Doctorate studies at Case Western Reserve University and Caltech. [Top]
Brock Reeve, MPhil, MBA
Executive Director, Harvard Stem Cell Institute
Brock Reeve, a graduate of Yale and the Harvard Business School, is Executive Director of the Harvard Stem Cell Institute. In partnership with the Faculty Directors, he has overall responsibility for the operations and strategy of the institute whose mission is to use stem cells, both as tools and as therapies, to understand and treat the root causes of leading degenerative diseases. HSCI is comprised of the schools of Harvard University and all its affiliated hospitals and research institutions. The institute currently has 79 principal faculty and 150 affiliated faculty. Under the leadership of the Executive Committee, HSCI invests in scientific research in three main areas – seed grants, core facilities and large-scale disease programs. Beyond the science, the institute also has programs to address ethics and public policy issues, to provide lab experiences for undergraduates, to educate high school science teachers, science journalists and the public at large. Brock comes to this role from the commercial sector with extensive experience in both management consulting and operations for technology-based companies, with a focus on life sciences. Brock’s business career started with the Boston Consulting Group. Prior to Harvard, Brock was COO and Managing Director of Life Science Insights, an IDC company, a consulting and market research firm specializing in information technology in life sciences. [Top]
Alan Regenberg, MBe
Bioethics Research Manager, Johns Hopkins Berman Institute of Bioethics
Alan Regenberg is a senior staff member at the Berman Institute, with active involvement in a wide range of research programs and initiatives. These include: The Bioethics Rapid Response Initiative; the Berman Institute Social Media Initiative; the Stem Cell Policy and Ethics (SCOPE) Program; the Program in Ethics and Brain Sciences (PEBS-Neuroethics); and the Hinxton Group – an international consortium on stem cells, ethics and law. Alan’s research interests are diverse, and have recently focused on issues in global health, stem cell science and neuroethics. Alan completed his undergraduate training in History and Psychology at Rutgers University, and received his Master of Bioethics degree from the Center for Bioethics at the University of Pennsylvania. Alan joined the Berman Institute in 2004. Prior to this, he was employed in multiple roles for an interdisciplinary, NIH-funded center researching depression in late life at the University of Pennsylvania. [Top]
Mark Rohrbaugh, PhD, JD (Observer)
Director, Office of Technology Transfer, National Institutes of Health
Mark L. Rohrbaugh has served since 2001 as Acting Director and then Director, Office of Technology Transfer (OTT), National Institutes of Health (NIH), Department of Health and Human Services (HHS). OTT manages the patenting and commercial licensing of NIH and FDA intramural inventions and serves as the lead office within the HHS for the development of intramural and extramural technology transfer policy. In fiscal year 2009 alone, OTT licensees reported 350 products and services on the market, generating combined sales of nearly $6B. Mark Rohrbaugh is Vice-Chair of the Public Health Service Technology Transfer Policy Board and serves on the National Science and Technology Council Technology Committee and the HHS Innovation Council. He advises the NIH and HHS on intellectual property issues involving a diverse range of biomedical technologies including stem cells, pandemic influenza, gene diagnostics, and technology transfer with developing countries. He has represented the HHS at the Organization for Economic Cooperation and Development (OECD) and the World Health Organization (WHO). Most recently, he was a member of the WHO Expert Working Group on R&D Financing. Mark Rohrbaugh previously held the position of Director, Office of Technology Development, National Institute of Allergy and Infectious Diseases (NIAID). Prior to joining the NIH, he conducted molecular and cell biology research at the University of Minnesota and two start-up biotechnology companies. He received his Ph.D. in biochemistry from The Pennsylvania State University and a degree in law (J.D.) with honors from The George Washington University Law School. [Top]
Kris Saha, PhD
Postdoctoral Fellow, Whitehead Institute for Biomedical Research, MIT Science Technology and Society Fellow, Kennedy School of Government, Harvard University
Krishanu Saha studied Chemical Engineering at Cornell University and at the University of California in Berkeley. In his dissertation he worked on experimental and computational analyses of neural stem cell development, as well as the design of new materials for adult stem cell culture. In 2007 he became a postdoctoral fellow in the laboratory of Professor Rudolf Jaenisch at the Whitehead Institute for Biomedical Research at MIT in Cambridge, Massachusetts. Concurrent with his laboratory research, he also works with Professor Sheila Jasanoff in the Program on Science, Technology and Society at the Kennedy School of Government at Harvard University. Since 2006 he has done research on human embryonic stem cells and the institutional policies surrounding them. As a Branco-Weiss Fellow, Kris Saha is expanding his background in working with nascent human engineered materials to investigate the modeling of diseases at the cellular level with human “reprogrammed” stem cell lines. [Top]
Julian Savulescu, BMedSci, MB, BS, MA, PhD
Chair in Practical Ethics, University of Oxford Director of the Oxford Uehiro Centre for Practical Ethics Director of the Program on Ethics and the New Biosciences in the 21st Century School, University of Oxford Professor Savulescu is engaged in research, education and stimulating open public discussion around the ethical issues which arise in everyday life and which are related to the changes in society, particularly those related to technological advancement. He has worked broadly in the ethics of science and medicine. His main current research interests are the ethics of the new biosciences: cloning, stem cells, genetics, artificial reproduction and neuroscience. Julian Savulescu is qualified in medicine, bioethics and analytic philosophy. He has published over 100 articles in journals such as the British Medical Journal, Lancet, Australasian Journal of Philosophy, Bioethics, the Journal of Medical Ethics, American Journal of Bioethics, Medical Journal of Australia and Philosophy, Psychiatry and Psychology. Previously, he was Editor of the Journal of Medical Ethics, the highest impact factor journal in medical and applied ethics. He was Director of the Ethics of Genetics Unit at the Murdoch Children’s Research Institute, Royal Children’s Hospital, Melbourne, Australia. He was also Director of the Bioethics Program at the Centre for the Study of Health and Society at the University of Melbourne and the Chair of the Department of Human Services, Victoria, Ethics Committee. He has worked as a Clinical Ethicist at the Oxford Radcliffe Hospitals. [Top]
Christopher Scott
Director, Program on Stem Cells in Society, Stanford University President/CEO, The Stem Cell Advisors, Inc
Christopher Thomas Scott is Director of the Stanford University Program on Stem Cells in Society, a faculty member and senior research scholar at the Stanford Center for Biomedical Ethics, a Brocher Institute Fellow and an associate fellow at King’s College, London and the University of Sheffield. He directs three Stanford courses on stem cell research. His academic interests focus on the social, economic, political and ethical dimensions of regenerative medicine. He has authored over 80 publications, chapters, and peer-reviewed papers. His popular and widely read book, Stem Cell Now (2007 Penguin/Plume) has been translated into four languages. He is a staff editor at Nature Biotechnology. Scott is the President and CEO of The Stem Cell Advisors, Inc (www.stemcelladvisors.com) a public benefit non-profit company providing stem cell research oversight for biotechnology and research institutions. Scott was the former Assistant Vice Chancellor at the University of California, San Francisco (UCSF), and there he was responsible for technology transfer, legal affairs, clinical research, and business development. While at UCSF, he founded the Program in Bioentrepreneurship, a training program and incubator for life sciences graduates. Scott was the co-founder of Acumen Sciences, a research and consulting company based in San Francisco and the founding executive editor of the award-winning Acumen Journal of Sciences, a magazine focused on life sciences business and policy. For nearly a decade Scott held senior management positions at Stanford. As Associate Director of the Center for Molecular Medicine, he worked with Nobel laureate Paul Berg to develop one of the nation’s first translational medicine programs. He co-founded SPECTRUM, a research unit devoted to clinical trials. During his tenure he led corporate development and directed research management for the medical center. He is one of only a handful of executives awarded for their contributions to Stanford’s research enterprise.Scott is an ethics and policy committee member for the International Society of Stem Cell Research, and a member of the Center for Biomedical Ethics. He is a past member of the Stanford Program in Genomics, Ethics and Society, and the California Health Care Initiative. [Top]
Mark Sheehan, PhD
Oxford BRC Ethics Fellow at the Ethox Centre and a James Martin Research Fellow in the Program on the Ethics of the New Biosciences
Mark Sheehan received his PhD in Philosophy from The City University of New York, where his work was primarily on moral philosophy. He is currently the Oxford BRC Ethics Fellow at the Ethox Centre and a James Martin Research Fellow in the Program on the Ethics of the New Biosciences. As BRC Ethics Fellow, Mark is involved in Research Ethics and Patient and Public Involvement (PPI) across the Oxford NIHR Biomedical Research Centre (BRC) themes. This involvement includes discussions with researchers about research ethics issues in their work, collaborating on research proposals with ethical components and conducting research on issues in research ethics, ethics generally and PPI that engage with the research themes within the BRC. With colleagues from the Centre for Professional Ethics at Keele University, he has just completed an EU-funded textbook on research ethics. As a member of the Program on the Ethics of the New Biosciences, Mark is involved in research identifying and critically analysing ethical issues and problems arising in stem cell science, cloning, artificial reproduction and genetics. The Program is part of the James Martin 21st Century School and so is also involved in numerous collaborations with other parts of the School.
He is a member of the Advisory Group for National Specialised Services (AGNSS) and the Thames Valley Priorities Forum (MOBBB) for the South Central Strategic Health Authority. He also sits on the University’s Social Sciences and Humanities Inter-Divisional Research Ethics Committee and is an external member of the Goldsmith’s Research Ethics Committee. He is a Senior Research Fellow in Philosophy at St. Benet’s Hall.
Current Research Themes: 1) Research Ethics and Governance, 2) Ethics and Reproductive Technologies, 3) Ethical issues in Resource Allocation, 4) Commercialisation and Health, 5) Methodology in Applied Ethics and Bioethics. [Top]
Glyn Stacey, PhD
Head of Division of Cell Biology and Imaging, National Institute for Biological Standards and Control Director, The UK Stem Cell Bank
Glyn Stacey is the Head of the Division of Cell Biology and Imaging at the National Institute for Biological Standards and Control (NIBSC). He is also Director for the UK Stem Cell Bank based at NIBSC. Dr. Stacey is the author and editor of a number of books on cell culture, microbiological safety and cell culture technology. He has also acted as an expert advisor to the World Health Organisation and the European Medicines Agency. He chairs the scientific advisory board of the Public Private Partnership Stem Cells for Safer Medicines, leads the International Stem Cell Banking Initiatve (funded by a consorium of more than 20 national funding agencies) and is a current member of the standardisation committee of the International Society for Stem Cell Research. His research interests include the safety and efficacy of cell therapy and the characterisation and suitability of a range of cell cultures used in the manufacture of biological medicines. [Top]
Jeremy Sugarman, MD, MPH, MA
Harvey M Meyerhoff Professor of Bioethics and Medicine, Johns Hopkins University Deputy Director for Medicine, Johns Hopkins Berman Institute of Bioethics
Jeremy Sugarman is the Harvey M Meyerhoff Professor of Bioethics and Medicine, Professor of Medicine, Professor of Health Policy and Management, and Deputy Director for Medicine of the Johns Hopkins Berman Institute of Bioethics. He served as Senior Policy and Research Analyst for the White House Advisory Committee on Human Radiation Experiments and as a consultant to the National Bioethics Advisory Commission for its project on international research ethics. In both of these roles, Dr Sugarman conducted empirical research to inform policy-making. Dr. Sugarman conducts both theoretical and empirical research in medical ethics. His work concentrates on informed consent, research ethics, and the ethical issues associated with emerging technologies. He is the author of over 175 publications in peer-reviewed journals. He has also edited or co-edited four books (Beyond Consent: Seeking Justice in Research; Ethics of Research with Human Subjects: Selected Policies and Resources; Ethics in Primary Care; and Methods in Medical Ethics). Dr. Sugarman is an associate editor of Clinical Trials, a contributing editor for IRB, and is on the editorial boards of Accountability in Research and Theoretical Medicine and Bioethics. Dr. Sugarman serves on the Scientific and Research Advisory Board for the Canadian Blood Service and is a member of the Maryland Stem Cell Research Commission. He is currently Chair for the Ethics Working Group of the HIV Prevention Trials Network, the Ethics Officer for the Resuscitation Outcomes Consortium, and Co-Chair of the Johns Hopkins Embryonic Stem Cell Research Oversight Committee. Dr Sugarman is a member of the American Society of Clinical Investigation and a Fellow of the American Association for the Advancement of Science, the American College of Physicians, and the Hastings Center. [Top]
John Sulston, PhD
Chair, Institute for Science, Ethics and Innovation, University of Manchester
John Sulston is Chair of the Institute for Science, Ethics and Innovation (iSEI), which was established at The University of Manchester with the mission to observe and analyse the role and responsibilities of science and innovation. The institute will examine the ways in which science is used in the 21st century, to evaluate possible or desirable changes and to consider the forms of regulation and control of the process that are appropriate or desired. John Sulston was awarded the Nobel Prize for Physiology or Medicine in 2002 jointly with Sydney Brenner and Bob Horvitz, for the work they had done in understanding the development of the nematode (worm) Caenorhabditis elegans. For more than 20 years, John worked on the biology of C. elegans, studying particularly its cell lineage and its genome. Collaboration between his group and that of Bob Waterston in St Louis, Missouri resulted in the publication of the nematode DNA sequence in 1998. John was the Founder Director of the Wellcome Trust Sanger Centre from 1992 to 2000, where one third of the task to sequence the human genome was completed. In 2002 he co-authored with Georgina Ferry The Common Thread, an account of the science, politics and ethics of the human genome project. He is a Fellow of the Royal Society and an Honorary Fellow of Pembroke College, Cambridge. [Top]
Patrick Taylor, JD
Fellow, Petrie-Flom Center for Health Law Policy, Biotechnology and Bioethics, Harvard Law School Assistant Clinical Professor, Harvard Medical School Staff Scientist, Children’s Hospital, Boston, MA
Patrick Taylor is a Fellow at the Petrie-Flom Center for Health Law Policy, Biotechnology and Bioethics at Harvard Law School, an Assistant Clinical Professor at Harvard Medical School, and a Staff Scientist at Children’s Hospital Boston. He graduated from the University of Wisconsin-Madison with a BA in Zoology and Philosophy, receiving Phi Beta Kappa and highest honors, and received his JD from Columbia University Law School with academic honors. He was a 2007-2008 Fellow in Medical Ethics at Harvard Medical School, and is an alumnus of the Harvard Business School 2008-2009 Program in Leadership Development. His academic work focuses on legal, ethical and policy issues in biomedical research, health care and biotechnology, in particular subjects in which law poorly translates ethics, or, conversely, ethics’ claim to legal influence is open to question. His writings, on subjects as diverse as stem cell research, public engagement in science policy-making, the role of IRBs in research conflicts of interest, justice and respect for persons in translational genomic research, clinical network development, patient-controlled electronic medical records, and the ethics of intellectual property, have appeared in Nature, Science, Cell, Nature Biotechnology, Science Translational Medicine, Cell Stem Cell, Academic Medicine, Science and Engineering Ethics, Drug Development, the Journal of the American Informatics Association, the American Bar Association’s Health Lawyer, the Journal of the New York State Bar Association and the New York Health Law Journal. His sole empirical study, examining whether state payer mandates for cancer clinical research incorporate scientific and ethical standards, was published in the Journal of the National Cancer Institute, and its recommendations were incorporated in the 2010 national health care reform legislation. He is a co-investigator on two NIH grants on returning individualized genetic research results to anonymized participants, and a consultant on a third, examining academic consulting arrangements. Professional associations include leadership positions with the Health Section of the New York State Bar Association, including as Chair of the Inhouse Counsel Committee, Vice-chair of the Legislation Committee and member of the Executive Committee; Co-chair of the Standards Committee of the International Society for Stem Cell Research (ISSCR); Chair of the Registry Committee of the ISSCR; member of the ISSCR Ethics and Public Policy Committee; member of the ISSCR Task Force on Guidelines for the Conduct of Human Embryonic Stem Cell Research and the ISSCR Task Force on Clinical Translation of Stem Cells; and chair of the most recent Task Force on Unproven Stem Cell Treatments. He has also served on two institutional review boards, the Children’s Hospital Embryonic Stem Cell Review and Oversight Committee, and the Harvard-wide Stem Cell Review and Oversight Committee. [Top]
Dieter Treichel, PhD
Patent and Start-up Manager, Max Planck Innovation
Dieter Treichel is the patent and start-up manager and jointly responsible for the evaluation of the scientific background and economic potential of inventions from the Max Planck Society. Before joining Max Planck Innovation, Dieter Treichel worked as investment manager for the Munich-based venture capital company FORUM Venture Capital AG and as business development manager for two FORUM portfolio companies. In 2003, he moved to the Max Planck Society as personal assistant to the president. Dieter Treichel studied biology at the Julius Maximilians University in Würzburg and at the State University of New York in Albany, USA. He finished his PhD thesis in Prof. Dr Peter Gruss’s group at the Max Planck Institute of Biophysical Chemistry in Göttingen, focusing on molecular mechanisms during mouse embryonic development. In addition, Dieter Treichel held the position as CSO at the RZPD – German Resource Center for Genome Research from May 2017 to May 2010. [Top]
David Winickoff, JD
Co-Director, Science, Technology, and Society Center, University of California Berkeley Associate Professor of Bioethics and Society, University of California Berkeley
David Winickoff is Associate Professor of Bioethics and Society at U.C. Berkeley, where he co-directs the Berkeley Science, Technology and Society Center. Trained at Yale (summa cum laude), Harvard Law School, and Cambridge University (Mellon Fellow), he has published over 30 articles in leading bioethics, biomedical, legal and science studies journals such as The New England Journal of Medicine, Trends in Biotechnology, and the Yale Journal of Health Policy, Law and Ethics. His academic and policy work spans topics of biotechnology law, intellectual property, geoengineering, food safety regimes, and human subjects research. He has authored or co-authored a number of articles on stem cell ethics and intellectual property. [Top]
Fanyi Zeng, PhD
Structural, Cell and Molecular Biology & Medical and Health Sciences
Shanghai Jiao Tong University
Dr. Fanyi Zeng obtained both of her graduate degrees from the University of Pennsylvania School of Medicine, and is currently Professor and Associate Director of Shanghai Institute of Medical Genetics and of Shanghai Stem Cell Institute, Shanghai Jiao Tong University School of Medicine. Dr. Zeng is Chief Scientist of a multi-institutional program project supported by the Ministry of Science and Technology’s Basic Science Research Program (“973”).
Professor Zeng’s research interests include topics in the fields of human genetics and developmental biology, and she has published in top scientific journals such as Nature, PNAS, Development, Human Mutation, Human Molecular Genetics, and Developmental Biology. Dr. Zeng began her research in the early 1990’s studyin the molecular mechanisms of hemoglobinopathies. She was among the first to identify the splicing defect responsible for one of the most common b-thalassemia disorders in the Chinese population, leading to the first successful treatment of this disease using hydroxyurea and the further development of therapies for the disease. She was the first to apply array-based MLPA technology for the molecular diagnosis of other common Chinese genetic disorders. Professor Zeng has identified important biological and molecular processes that accompany and likely underlie the three major transitions during embryogenesis. Further, she has described RNA expression during zygotic gene activation and identified key genes important for early preimplantation embryo development. Dr. Zeng uses large animal models to study human disease interventions, bioreactor development, and improvement of animal cloning efficiencies. Most notably, Dr. Zeng successfully described the engraftment and differentiation of human hematopoietic stem cells in an in vivo system using a human/goat chimera model. Dr. Zeng recently worked with Dr. Qi Zhou’s group at the Chinese Academy of Science to report the generation of live-born mice from iPS cells through tetraploid complementation, providing the first, definitive evidence that these induced stem cells are truly pluripotent, a characteristic shared with embryonic stem cells. These projects were selected among the top ten achievements in basic science research in China in 2006 and 2009 as well as one of the top ten scientific advancements of 2009 by the China Ministry of Science and Technology.
Other awards Dr. Zeng has received include the First Young Woman Scientist Award from the Third World Organization of Women in Science (TWOWS), the 6th China Outstanding Young Woman Scientists Award, and the 10th National Award for Achievement of Science and Technology. Dr. Zeng actively serves the scientific community as a founding member of the Chinese Society of Stem Cell Biology and is currently the first Secretary General of the Society; she is also the Chinese representative to the Ethics Working Party of the International Stem Cell Forum. [Top]
Proprietary Challenges in Stem Cell Research 